Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream

University of Calgary

$100,000.00

The HIV-1 Reservoir in the Gut

EF 2011-12

Résumé
Despite the advances made in the treatment and understanding of infection and pathogenesis by Human Immunodeficiency virus (HIV), the causative agent of AIDS, there is still no cure or vaccine for this devastating infection. The main problem with HIV-1 is its ability to mutate with high frequency, complicating the design of vaccines or antiviral drugs. HIV infects many different tissues and organs in the human body; one of these is the gut. As not all tissues and organs are targeted with the same efficiency by the currently available drugs, HIV can hide from therapeutic interventions. Apart from being a hide out for HIV from antiviral drugs these different tissues and organs can also form a source of more pathogenic HIV strains. We will identify the different HIV strains found in the gut with regard to antiviral drug resistance and their pathogenic properties. This will give insight in the role of the gut as a source of drug resistant and more pathogenic HIV strains, and how this is affected by therapeutic interventions. Alterations in therapy together with other host factors could facilitate viral evolution toward drug resistance or increased pathogenicity. In addition, we will also address the disease mechanisms underlying the diseases induced by HIV in the gut. Expanding our understanding of the HIV varieties found in different tissues, such as the gut, in the HIV infected individual is essential for developing more effective therapeutic strategies for people infected by HIV in both the developed and the developing countries.
Programme
Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
250802
Name
van Marle Guido
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
The HIV-1 Reservoir in the Gut
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream
Keyworddelim
Antiretroviral Drug Resistance; Gastrointestinal Inflammation; Gastrointestinal Pathogenesis; Human Immunodeficiency Virus Type 1; Viral Diversity And Evolution
Abstract
Despite the advances made in the treatment and understanding of infection and pathogenesis by Human Immunodeficiency virus (HIV), the causative agent of AIDS, there is still no cure or vaccine for this devastating infection. The main problem with HIV-1 is its ability to mutate with high frequency, complicating the design of vaccines or antiviral drugs. HIV infects many different tissues and organs in the human body; one of these is the gut. As not all tissues and organs are targeted with the same efficiency by the currently available drugs, HIV can hide from therapeutic interventions. Apart from being a hide out for HIV from antiviral drugs these different tissues and organs can also form a source of more pathogenic HIV strains. We will identify the different HIV strains found in the gut with regard to antiviral drug resistance and their pathogenic properties. This will give insight in the role of the gut as a source of drug resistant and more pathogenic HIV strains, and how this is affected by therapeutic interventions. Alterations in therapy together with other host factors could facilitate viral evolution toward drug resistance or increased pathogenicity. In addition, we will also address the disease mechanisms underlying the diseases induced by HIV in the gut. Expanding our understanding of the HIV varieties found in different tissues, such as the gut, in the HIV infected individual is essential for developing more effective therapeutic strategies for people infected by HIV in both the developed and the developing countries.
Competitiondate
201109
Approvedterm2
1 yr 0 mth
Pinamesdelim
van Marle, Guido
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~